铁和癌症:当铁转向瘤时
Shinya Toyokuni1,2,3, Yingyi Kong4, Yuki Maeda4
1Department of Pathology and Biological Responses, Nagoya University Graduate School of Medicine, 65 Tsurumai-cho, Showa-ku, Nagoya, 466-8550, Japan. toyokuni@med.nagoya-u.ac.jp.
Cellular and molecular life sciences : CMLS
|November 25, 2025
概括
铁亡,一种由铁驱动的细胞死亡,在癌症中起着双重作用,既作为抑制剂,又作为治疗点. 了解癌症中的铁成是开发新治疗方法的关键.
科学领域:
- 在瘤学瘤学.
- 细胞死亡机制 细胞死亡机制
- 生物化学 生物化学
背景情况:
- 铁亡是依赖铁的调节性亡,由脂质过氧化驱动,在癌症生物学中越来越重要.
- 癌细胞发展出适应性来逃避铁亡,例如加强xCT-CD44v轴和GPX4活动.
- 铁生可以通过释放激活免疫细胞的信号来诱导免疫反应 (免疫铁生).
研究的目的:
- 探索铁在癌症发生和癌症中铁脱离中的作用.
- 研究针对铁性癌症的新型治疗策略.
- 了解耐铁灭症的诊断标志物和遗传背景.
主要方法:
- 使用铁二三酸盐 (Fe-NTA) 鼠标模型研究慢性芬顿化学及其影响.
- 分析癌细胞的适应,包括抗氧化剂程序和线粒体重塑.
- 研究低温等离子体 (LTP) 作为诱导铁亡的一种方式.
主要成果:
- 在Fe-NTA模型中,慢性铁暴露会诱导DNA损伤,并选择耐铁灭的克隆.
- 癌细胞表现出增强的抗氧化防御和特定的轴增强,以幸存ferroptosis.
- 经HNE修饰的蛋白质是脂质过氧化的标记物,而Fe (II) 可视化需要特定的成像技术.
结论:
- 铁亡是一种内在的瘤抑制机制和治疗脆弱性.
- 通过利用铁死来准癌症中的铁是一种有前途的治疗策略.
- 在遗传性综合征中,缺陷的基因组维护与铁死耐药性有关.
相关概念视频
Necrosis
6.3K
Necrosis is considered as an “accidental” or unexpected form of cell death that ends in cell lysis. The first noticeable mention of “necrosis” was in 1859 when Rudolf Virchow used this term to describe advanced tissue breakdown in his compilation titled “Cell Pathology”.
Morphological Manifestations of Necrosis
Necrotic cells show different types of morphological appearance depending on the type of tissue and infection. In coagulative necrosis, cells become...
Morphological Manifestations of Necrosis
Necrotic cells show different types of morphological appearance depending on the type of tissue and infection. In coagulative necrosis, cells become...
6.3K
mTOR Signaling and Cancer Progression
4.6K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
4.6K
Electron Transport Chain: Complex I and II
18.4K
The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...
ROS generation is regulated and maintained at moderate levels necessary...
18.4K
Cancer Prevention
7.6K
Several factors can increase the risk of cancer in an individual. About 50% of cancer cases can be prevented by adopting a healthy lifestyle, regular exercise, eating healthy, and following a modest cancer prevention diet. Epidemiological studies have consistently shown that populations with vegetable and fruit-rich diets have reduced the incidence of cancer. On the other hand, populations who have a diet rich in animal fat, red meat, junk food, or high calories are predisposed to cancer.
Some...
Some...
7.6K
Adaptive Mechanisms in Cancer Cells
6.9K
Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
6.9K
Targeted Cancer Therapies
8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.6K

